Virtus Investment Advisers Inc. Cuts Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Virtus Investment Advisers Inc. lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 80.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,980 shares of the biotechnology company's stock after selling 62,917 shares during the quarter. Virtus Investment Advisers Inc.'s holdings in ADMA Biologics were worth $257,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ADMA. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $51,000. AlphaQuest LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $84,000. CIBC Private Wealth Group LLC raised its position in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its position in shares of ADMA Biologics by 303.4% during the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock valued at $98,000 after buying an additional 4,312 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.04 during mid-day trading on Thursday, reaching $20.16. The company's stock had a trading volume of 1,739,151 shares, compared to its average volume of 3,702,133. ADMA Biologics, Inc. has a 12-month low of $9.35 and a 12-month high of $25.67. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm's fifty day moving average price is $20.64 and its two-hundred day moving average price is $18.91. The stock has a market cap of $4.81 billion, a P/E ratio of 72.00 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the previous year, the company earned $0.08 EPS. The business's quarterly revenue was up 40.2% compared to the same quarter last year. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James lifted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.